(firstQuint)Safety and Efficacy of Folfox4 + Weekly Cetuximab vs Folfox 4+Biweekly Cetuximab by Metastatic Colorectal Cancer.

 This multicenter randomized phase II study will enroll approximately 150 patients with metastatic Colorectal Cancer.

 Patients are randomized in Arm A(FOLFOX4 in combination with weekly Cetuximab) or Arm B (FOLFOX4 in combination with biweekly Cetuximab).

 Both efficacy and safety data will be collected.

 The investigator will assess response to treatment every 8 weeks based on the imaging.

 Following permanent treatment cessation, patients will be followed-up for survival.

.

 Safety and Efficacy of Folfox4 + Weekly Cetuximab vs Folfox 4+Biweekly Cetuximab by Metastatic Colorectal Cancer@highlight

To assess the efficacy of FOLFOX4 in combination with cetuximab, weekly and FOLFOX4 in combination with cetuximab, biweekly.

